Last reviewed · How we verify
NCT04194021: NewHorizon
Characteristics and Outcomes of Patients Who Received Etravirine and/or Darunavir
trial in HIV/AIDS in 871 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Elizabeth Glaser Pediatric AIDS Foundation |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 871 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2023 |
| Sites | 5 locations across Cameroon, Lesotho, Kenya, Eswatini, Uganda |
Conditions studied
- HIV/AIDS — all drugs for HIV/AIDS →
Sponsor
Elizabeth Glaser Pediatric AIDS Foundation
Who can join
Under 25, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives of this data collection activity are to: 1. Describe the baseline demographics, clinical and laboratory profile of patients who ever received darunavir (DRV) and/or etravirine (ETR), at the time of initiation on DRV and/or ETR; 2. Describe the clinical and laboratory profile of patients who ever received DRV and/or ETR every 6 months from the first data collection point through 2021; 3. Describe dynamics in HIV drug resistance mutations among patients who fail treatment on new regimens including DRV and/or ETR; 4. Describe demographics, clinical and laboratory profile of young adults who transition out of the donation program after the age of 25 years at 12 months after their transition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04194021
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV/AIDS
Currently open trials in the same condition.
- NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
- NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
- NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
- NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
- NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting
Other Elizabeth Glaser Pediatric AIDS Foundation trials
Trials by the same sponsor.
- NCT05684887 — Digital Tools to Expand COVID-19 Testing in Exposed Individuals in Cameroon · NA · completed
- NCT05529771 — Clinical Outcomes of paTients pREsenting to HArare COVID-19 CenTer of Excellence With SARS-CoV-2 Infection · completed
- NCT05458557 — Antigen Rapid Diagnostic Tests for Community Identification of Severe Acute Respiratory Syndrome Coronavirus 2 · completed
- NCT05382130 — INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya · NA · completed
- NCT05498727 — Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04194021 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Elizabeth Glaser Pediatric AIDS Foundation
- Last refreshed: 18 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04194021.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing